{
    "clinical_study": {
        "@rank": "85847", 
        "arm_group": [
            {
                "arm_group_label": "Timolol", 
                "arm_group_type": "Active Comparator", 
                "description": "Timolol eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection"
            }, 
            {
                "arm_group_label": "Brimonidine", 
                "arm_group_type": "Active Comparator", 
                "description": "Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection"
            }, 
            {
                "arm_group_label": "Acetazolamide", 
                "arm_group_type": "Active Comparator", 
                "description": "Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection"
            }, 
            {
                "arm_group_label": "Mannitol", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Sham Comparator", 
                "description": "Artificial tears, 2 drops, 1-2 hours before intravitreal injection"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the effect of prophylactic antiglaucoma agents in prevention of acute intraocular\n      pressure rise after intravitreal injection."
        }, 
        "brief_title": "Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Intraocular Pressure Change in Intravitreal Injection", 
        "detailed_description": {
            "textblock": "Acute intraocular pressure elevation after intravitreal injection of bevacizumab was\n      proven.Acute intraocular pressure elevation most probably is volume related and long term\n      intraocular pressure elevation relates to pharmacologic features of the medications which\n      results in anatomic changes in the angle of anterior chamber.Numerous studies found an\n      intraocular pressure elevation right after the injection and quick normalization within\n      maximally 30 minutes.This  intraocular pressure elevation which lasts about 30 minutes, can\n      result in irreversible visual loss especially in patients with critical remaining nerve\n      fibers in the optic nerve head, as occurs in glaucomatous patients. Is there any way to\n      prevent or even shorten this time of intraocular pressure elevation? We tried in our study\n      to find a suitable response for a question above, so we used several anti-glaucoma agents\n      (Timolol, Brimonidine, Acetazolamide, Mannitol versus placebo) as a prophylaxis to prevent\n      acute intraocular pressure elevation right after intravitreal bevacizumab injection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  all patients who candidate for receiving intravitreal bevacizumab\n\n        Exclusion Criteria:\n\n          -  patients who had advanced glaucoma\n\n          -  patients who received antiglaucoma agents in the past\n\n          -  patients who had corneal scar which affect IOP measurement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02140450", 
            "org_study_id": "910292"
        }, 
        "intervention": [
            {
                "arm_group_label": "Timolol", 
                "description": "2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection", 
                "intervention_name": "Timolol", 
                "intervention_type": "Drug", 
                "other_name": "Timoptic"
            }, 
            {
                "arm_group_label": "Brimonidine", 
                "description": "Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection", 
                "intervention_name": "Brimonidine", 
                "intervention_type": "Drug", 
                "other_name": "Alphagan"
            }, 
            {
                "arm_group_label": "Acetazolamide", 
                "description": "Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection", 
                "intervention_name": "Acetazolamide", 
                "intervention_type": "Drug", 
                "other_name": "Diamox"
            }, 
            {
                "arm_group_label": "Mannitol", 
                "description": "Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection", 
                "intervention_name": "Mannitol", 
                "intervention_type": "Drug", 
                "other_name": "Mannitol"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Artificial tears, 2 drops, 1-2 hours before intravitreal injection", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Sham"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetazolamide", 
                "Mannitol", 
                "Timolol", 
                "Brimonidine", 
                "Bevacizumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "intraocular pressure, intravitreal injection, short term", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mashhad", 
                    "country": "Iran, Islamic Republic of", 
                    "state": "Khorasan Razavi"
                }, 
                "name": "Retina Research Center, Khatam eye Hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "5", 
        "official_title": "Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection: the Effect of Pretreatment With Antiglaucoma Agents", 
        "overall_official": {
            "affiliation": "Retina Research Center, Mashhad University of Medical Sciences, Mashhad, Iran", 
            "last_name": "Nasser Shoeibi, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Iran: Ministry of Health", 
                "Iran: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "the change in intraocular pressure after intravitreal injection of bevacizumab", 
            "measure": "change in IOP", 
            "safety_issue": "No", 
            "time_frame": "0, 5, 10, 15, 30 minutes after injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02140450"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mashhad University of Medical Sciences", 
            "investigator_full_name": "Nasser Shoeibi", 
            "investigator_title": "Assistant Professor of Ophthalmology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mashhad University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mashhad University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}